HeartMate II Left Ventricular Assist Device Pump Exchange: A Single-Institution Experience

Abstract

Background Left ventricular assist devices (LVADs) have revolutionized the treatment of patients with end-stage heart failure. These devices are replaced when pump complications arise if heart transplant is not possible. We present our experience with HeartMate II (HMII (Thoratec, Plesanton, California, United States)) LVAD pump exchange.

Materials and Methods We retrospectively reviewed all cases that required pump exchange due to LVAD complication from November 2011 until June 2016 at a single high-volume institution. The indications, demographics, and outcome were extracted and analyzed.

Results Of 250 total patients with implanted HMII LVADs, 16 (6%) required pump exchange during the study period. The initial indications for LVAD placement in these patients were bridge to transplantation (n = 6 [37.5%]) or destination therapy (n = 10 [62.5%]). Fifteen patients (93.8%) required pump exchange due to pump thrombosis and 1 (6.2%) due to refractory driveline infection. Nine patients (56.2%) underwent repeat median sternotomy while a left subcostal approach was used in the remaining seven patients. Fifteen patients (93.7%) survived until hospital discharge. During the follow-up period (median, 155 days), 11 patients remained alive and 4 of these underwent successful cardiac transplantation.

Conclusion HMII LVAD pump exchange can be safely performed for driveline infection or pump thrombosis when heart transplantation is not an option.

Keywords

heart failure - circulatory assist devices - LVAD

• References

• 1 Hannan MM, Husain S, Mattner F. , et al; International Society for Heart and Lung Transplantation. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. J Heart Lung Transplant 2011; 30 (04) 375-384
• 2 Slaughter MS, Rogers JG, Milano CA. , et al; HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361 (23) 2241-2251
• 3 Taghavi S, Ward C, Jayarajan SN, Gaughan J, Wilson LM, Mangi AA. Surgical technique influences HeartMate II left ventricular assist device thrombosis. Ann Thorac Surg 2013; 96 (04) 1259-1265
• 4 Rose EA, Gelijns AC, Moskowitz AJ. , et al; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345 (20) 1435-1443
• 5 McCarthy FH, Kobrin D, Rame JE. , et al. Increasing frequency of left ventricular assist device exchanges in the United States. Ann Thorac Surg 2015; 100 (05) 1660-1664 , discussion 1665
• 6 Smedira NG, Blackstone EH, Ehrlinger J. , et al. Current risks of HeartMate II pump thrombosis: non-parametric analysis of Interagency Registry for Mechanically Assisted Circulatory Support data. J Heart Lung Transplant 2015; 34 (12) 1527-1534
• 7 Soleimani B, Stephenson ER, Price LC, El-Banayosy A, Pae WE. Clinical experience with sternotomy versus subcostal approach for exchange of HeartMate II left ventricular assist device. Ann Thorac Surg 2015; 100 (05) 1577-1580
• 8 Woo YJ, Acker MA. Implantable ventricular assist device exchange with focused intravascular deairing techniques. Ann Thorac Surg 2011; 91 (01) 306-307
• 9 Levin MA, Anyanwu AC, Eggert CA, Mittnacht AJ. Use of an automatic internal defibrillator to induce and maintain ventricular fibrillation during left ventricular assist device pump exchange. J Thorac Cardiovasc Surg 2014; 147 (03) e17-e18
• 10 Sabik JF, Nemeh H, Lytle BW. , et al. Cannulation of the axillary artery with a side graft reduces morbidity. Ann Thorac Surg 2004; 77 (04) 1315-1320
• 11 Oezpeker C, Zittermann A, Ensminger S. , et al. Systemic thrombolysis versus device exchange for pump thrombosis management: a single-center experience. ASAIO J 2016; 62 (03) 246-251
• 12 Moazami N, Milano CA, John R. , et al; HeartMate II Investigators. Pump replacement for left ventricular assist device failure can be done safely and is associated with low mortality. Ann Thorac Surg 2013; 95 (02) 500-505
• 13 Chamogeorgakis T, Koval CE, Smedira NG, Starling RC, Gonzalez-Stawinski GV. Outcomes associated with surgical management of infections related to the HeartMate II left ventricular assist device: Implications for destination therapy patients. J Heart Lung Transplant 2012; 31 (08) 904-906
• 14 Tong MZ, Smedira NG, Soltesz EG. , et al. Outcomes of heart transplant after left ventricular assist device specific and related infection. Ann Thorac Surg 2015; 100 (04) 1292-1297